On Invalid Date, Agile Therapeutics (NASDAQ: AGRX) reported Q2 2022 earnings per share (EPS) of -$2.71, up 66.13% year over year. Total Agile Therapeutics earnings for the quarter were -$12.22 million. In the same quarter last year, Agile Therapeutics's earnings per share (EPS) was -$8.00.
As of Q4 2022, Agile Therapeutics's earnings has grown year over year. Agile Therapeutics's earnings in the past year totalled -$64.12 million.
What is AGRX's earnings date?
Agile Therapeutics's earnings date is Invalid Date. Add AGRX to your watchlist to be reminded of AGRX's next earnings announcement.
What was AGRX's revenue last quarter?
On Invalid Date, Agile Therapeutics (NASDAQ: AGRX) reported Q2 2022 revenue of $2.13 million up 79.41% year over year. In the same quarter last year, Agile Therapeutics's revenue was $1.19 million.
What was AGRX's revenue growth in the past year?
As of Q4 2022, Agile Therapeutics's revenue has grown 226.24% year over year. This is 4.93 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 231.18%. Agile Therapeutics's revenue in the past year totalled $6.69 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.